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ABSTRACT 
 
Active, as well as passive cigarette smoke exposure is detrimental to the human health, 
negatively affecting the cardiovascular, respiratory and immune systems. In addition, it is 
also carcinogenic. 
The present thesis focused on the effects of cigarette smoke and two of its major components 
nicotine and endotoxin (lipopolysaccharide, LPS) on airway hyperreactivity (AHR) and 
inflammation, in both the lower and upper airways. The roles of nicotine and LPS were 
analyzed in murine in vitro and in vivo models. Further, the effects of smoking on the 
expressions of activin receptor-like kinases (ALK) were analyzed in tonsils from heavy 
smokers and matching non-smokers. 
The first four papers of this thesis illustrated the highly complex interactions induced by 
nicotine and LPS involving direct airway smooth muscle contractions, indirect nerve-
mediated airway contractions and epithelium-dependent relaxations. Short-term exposure (1 
day) to nicotine in an in vitro organ culture model resulted in decreased epithelium-dependent 
airway relaxations via cyclooxygenase (COX) and microsomal prostaglandin E synthase 1 
(mPGES-1) pathways. Long-term exposure (4 days) in the same model caused increased 
smooth-muscle-mediated airway contractions via transcriptional upregulation of kinin-
receptors, involving mitogen-activated protein kinase (MAPK) c-Jun N-terminal kinases 
(JNK) and phosphodiesterase (PDE) 4 pathways. In parallel, JNK-mediated transcriptional 
upregulation of toll-like receptors (TLR) was also seen. This resulted in enhanced contractile 
responses to the prototypical TLR4 agonist LPS, but at the same time decreased LPS-
mediated AHR to electric field stimulation (EFS). In analogy with the latter, in vivo 
experiments using subcutaneously implanted pumps that delivered nicotine during 24 
consecutive days, followed by 3 days of intranasally instilled LPS, demonstrated that the 
AHR induced by LPS was markedly decreased in the nicotine-treated mice. This highlighted 
the role of neuronal mechanisms in the development of lower airway AHR. 
The fifth paper used human tonsils to investigate the effect of chronic cigarette smoke 
exposure on the expression of ALK. A novel cotinine assay was developed to quantify the 
level of cigarette smoke exposure in tonsil homogenates.  Results showed a positive 
correlation between increased levels of smoke exposure and increased tonsillar mRNA 
expressions of IL-8, ALK1 and 2. 
In conclusion, both nicotine and LPS contribute to the development of AHR. Nicotine 
modulates the response to LPS in murine models both in vitro and in vivo. Altered ALK 
expressions in smokers may contribute to the poor prognosis that characterizes tonsillar 
cancer among smokers. These results may contribute to the development of specific and 
personalized treatment strategies for patients that are actively or passively exposed to nicotine 
or cigarette smoke. 
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1 BACKGROUND 
 
1.1 AIRWAY HYPERREACTIVITY 
 
Airway hyperreactivity (AHR) is a major and defining feature of asthma and to a lesser 
extent chronic obstructive lung diseases (COPD). It is defined as an exaggerated 
bronchoconstrictor response to direct pharmacological stimuli, such as histamine and 
methacholine, or indirect stimuli, such as exercise, cold air and hyperventilation (Cockcroft 
et al., 2006).   
The hyperactive phenotype of airway smooth muscle (ASM) is believed to be the primary 
cause of AHR. Bronchodilators, such as -agonists, have therefore always played a central 
role in the treatment of AHR, both as rescue and maintenance therapy (Cazzola et al., 2012). 
However, the use of long-acting -agonists alone has been controversial and it is 
recommended that long-acting -agonists should not be taken without simultaneous treatment 
with inhaled corticosteroids (Beasley et al., 2010).  
The relationship between airway inflammation and AHR is complex. AHR is believed to be 
a consequence of airway inflammation. Numerous studies have shown a positive 
correlation between inflammatory cell counts in bronchoalveolar lavage (BAL) and AHR 
(Cockcroft et al., 2006). However, a number of other studies in both patients (Crimi et al., 
1998; Singapuri et al., 2010) and animal models (Starkhammar et al., 2012; Swedin et al., 
2009) have also suggested that inflammation and development of AHR can be two 
dissociated events.  
ASM function can be regulated by the airway epithelium. The airway epithelium not only 
acts as a simple mechanical barrier, but also expresses a range of pattern-recognition 
receptors (PRR) and produces a number of important inflammatory mediators (Lambrecht et 
al., 2012), as well as bronchoactive substances including acetylcholine (Proskocil et al., 
2004), prostaglandin E2 (PGE2) (Balzary et al., 2006) and nitric oxide (NO) (Gourgoulianis et 
al., 1998). A recent study has shown that bradykinin can also be an important mediator in 
human ASM and epithelium interaction (Deacon et al., 2015). 
Neuronal regulation of AHR has long been recognized. Parasympathetic fibers innervating 
the ASM, vascular smooth muscle and glands regulate smooth muscle tone and mucus 
secretion. Hypersensitive nerves can therefore lead to AHR with symptoms such as cough 
and dyspnea (Undem et al., 2009). In the 1950s, surgical denervation and vagotomy were 
performed to treat severe asthma (Levine et al., 1950) and COPD (Abbott et al., 1953). This 
procedure indeed gave temporary relief of symptoms, but has been abandoned due to high 
complication risks and the introduction of more effective pharmacological treatment options 
targeting inflammation or smooth muscle. Interest in neuronal mechanisms has been 
revitalized during the recent years due the increasing recognition of the roll of neuronal 
transient receptor potential channels in airway diseases (Grace et al., 2014). 
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1.1.1 Cigarette smoking 
 
Tobacco smoke is a composite of irritant molecules, including nicotine, acetaldehyde, 
formaldehyde, nitrogen oxides and heavy metals. It is well-known that both active and 
passive cigarette smoke exposure cause increased AHR (Janson et al., 2001; Menon et al., 
1992). In addition, smoke-addicted asthmatics constitute a subgroup with a poor response to 
local corticosteroid treatment (Comhair et al., 2011; Stapleton et al., 2011). Maternal 
cigarette smoking (Strachan et al., 1998) and passive smoke exposure during childhood 
(Tinuoye et al., 2013) both increase the risk for wheezing in early life and the development of 
childhood asthma. 
Similar observations have been made in laboratory animals. Mice repeatedly exposed to side-
stream cigarette smoke exhibit increased airway contractile responses to carbachol, 
endothelin-1 (ET-1) and potassium (Lei et al., 2008), while chronically exposed guinea pigs 
exhibit increased airway reactivity to bradykinin and capsaicin, without altering their 
responses to methacholine or histamine (Bergren, 2001). This suggests that bradykinin plays 
an important role in tobacco smoke-induced AHR.  
Nicotine is the main addictive compound in cigarette smoke and also freely available over-
the-counter as a smoke cessation aid. Once inhaled, nicotine is quickly taken up by the 
bloodstream and distributed throughout the body, to act primarily on nicotinic acetylcholine 
receptors, leading to the classical symptoms of heart palpitation and increased blood pressure.  
Acute nicotine exposure causes a transient mild airway relaxation (Streck et al., 2010), 
whereas the effects of long-term exposure on the respiratory system are much more complex. 
Many of the detrimental health effects of cigarette-smoke are believed to be due to the ability 
of nicotine to affect the immune system, leading to both inflammatory (Vassallo et al., 2008) 
and anti-inflammatory effects (Wang et al., 2003). The effect of nicotine on AHR is however 
less studied.  
 
1.1.2 Toll-like receptors 
 
Toll-like receptors (TLR) are the most well-known family of PRR. They are essential 
components of the innate immune system, and are found on a variety of airway cells 
including epithelial, smooth muscle and infiltrating inflammatory cells. Thirteen TLRs have 
been identified in mice and four sets of them can be found on the cell surface. They recognize 
conserved microbial patterns such as lipopolysaccharide (LPS) of Gram-negative bacteria 
(TLR4), lipoteichoic acids of Gram-positive bacteria and bacterial lipoproteins (TLR1/TLR2 
and TLR2/TLR6), flagellin (TLR5) and Toxoplasma gondii profilin-like proteins (TLR11) 
(Akira et al., 2006). Our group has previously shown that TLR is widely expressed and 
functional on human airway smooth muscle (Mansson Kvarnhammar et al., 2013). 
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Dysregulation in airway TLR expression can lead to both acute and chronic inflammatory 
lung diseases including asthma and COPD (Lafferty et al., 2010). The “hygiene hypothesis” 
suggests that microbial infections, especially during childhood, can protect us from 
developing allergic diseases such as asthma (Tantisira et al., 2001). However, there are also 
studies suggesting that certain infections, such as respiratory syncytial viruses and 
rhinoviruses in childhood increase the risk of asthma later in life (Feldman et al., 2015). The 
role of TLRs in our innate immune defense against microbial infections has led to the 
speculation that TLR signaling pathways might be involved in the regulation of the extremely 
delicate balance in Th1/Th2 responses, and thus depending on the activation pattern, either 
prevents or promotes asthmatic diseases (Schroder et al., 2007).  
LPS is a prototypical TLR agonist primarily activating TLR4. It is an important component 
of the Gram-negative bacterial cell wall and often utilized to model the effect of bacterial 
infections under experimental conditions. LPS has long been known to be an active 
component of cigarette smoke (Hasday et al., 1999). In fact, cigarette smoke is one of the 
major sources of LPS in indoor environments (Larsson et al., 2004). Exposure to LPS in both 
occupational environments (Larsson et al., 1994; Vogelzang et al., 1998) and at home 
(Michel et al., 1996) has been shown to negatively affect respiratory health and lung function. 
Our group has shown that activation of TLR4 by LPS can cause AHR both in isolated airway 
segments (Bachar et al., 2004) and in an in vivo mouse model (Starkhammar et al., 2012). 
 
1.1.3 Bradykinin and related kinins 
 
Bradykinin and related kinins are peptides that act as pro-inflammatory mediators. They are 
produced from both blood (plasma kallikrein-kinin system) and local tissue (tissue kallikrein-
kinin system) in response to inflammatory stimuli. Bradykinin is formed from the kininogen 
precursor after proteolytic cleavage by the enzyme kallikrein. It can be further converted by 
carboxypeptidase N (kinase I) to des-Arg
9
-bradykinin. Both bradykinin and des-Arg
9
-
bradykinin are degraded by kininase II, an enzyme identical to angiotensin-converting 
enzyme and neutral endopeptidase (Moreau et al., 2005; Zhang et al., 2013). It has been 
proposed that accumulation of bradykinin might be the mechanism behind angiotensin 
converting enzyme inhibitor induced cough and angioedema (Fox et al., 1996; Mahmoudpour 
et al., 2013). 
Two classes of kinin receptor ligands are recognized by the corresponding receptor subtypes: 
B1 and B2 receptors, both belonging to the family of G-protein coupled receptors (GPCR). 
Kinin B1 receptors are expressed at low levels in healthy tissue but induced following 
inflammatory stimuli, whereas the kinin B2 receptors are constitutively expressed. The 
actions of bradykinin are mainly mediated by the B2 receptors, whereas the actions of des-
Arg
9
-bradykinin are mainly mediated by the B1 receptors (Leeb-Lundberg et al., 2005; Zhang 
et al., 2004). Icatibant, the selective antagonist for the kinin B2 receptor has been approved 
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for the treatment of hereditary angioedema within the European Union since 2008 (Wu et al., 
2015). 
Increased levels of bradykinin are found in BAL of asthmatics following allergen challenge 
(Christiansen et al., 1992). Directly inhaled bradykinin causes a potent bronchoconstriction in 
asthmatic patients, but even in high concentrations has no effect in healthy individuals 
(Barnes, 1992). Thus, bradykinin has occasionally been suggested as a marker, more sensitive 
than methacholine, for demonstrating AHR (Berman et al., 1995; Suguikawa et al., 2009).   
In murine models, the kinin receptors mediate both bronchoconstriction and epithelium-
dependent airway relaxations, as well as mucus secretion, edema and cough. Effects are 
dependent on the localization of the receptor and the pre-contractile state. Relaxations have 
been shown to be caused by the release of the cyclooxygenase (COX) product and 
bronchodilator PGE2 (Li et al., 1998). Kinin B1 receptors have also been suggested to be 
essential for LPS-induced AHR and acute lung injury in mice (Campanholle et al., 2010). In 
guinea pig, chronic exposure to tobacco smoke increases the airway reactivity to bradykinin 
without altering the response to methacholine or histamine (Bergren, 2001), suggesting a 
special role for bradykinin in smoke-induced AHR.  
 
1.1.4 Mitogen-activated protein kinases 
 
The mitogen-activated protein kinases (MAPK) signaling cascade is composed of a family of 
protein kinases whose functions and regulations have been conserved during evolution. There 
are at least three main groups of MAPK in mammalian cells including extracellular signal-
regulated protein kinase 1/2 (ERK1/2), p38 and c-Jun N-terminal kinase (JNK). They are 
activated by a three-tiered sequential phosphorylation starting from MAPK kinase kinase, 
MAPK kinase to MAPK, and are inactivated by MAPK phosphatases. 
Once activated, MAPKs can induce translocation and activation of their downstream 
transcriptional factors to regulate gene expression (Duan et al., 2006). In airways, MAPK 
activation can lead to ASM proliferation (Hirst et al., 2000), cytokine production (Hayashi et 
al., 2000) and mucus hypersecretion (Chen et al., 2001; Zhang et al., 2013). 
Studies in animal models have revealed that the activities of ERK1/2 (Kumar et al., 2003), 
p38 (Taube et al., 2004) and JNK (Nath et al., 2005) in the lungs are enhanced in allergic 
airway inflammation and AHR. Endobronchial biopsies of asthmatic patients show 
significant phosphorylation of ERK1/2 and p38 compared to controls. The degree of 
phosphorylation also correlates positively with the severity of the disease (Liu et al., 2008). 
Our group has shown that cytokines increase AHR to bradykinin in vitro via activation of 
JNK and downstream transcription factor nuclear factor-kappaB (NF-κB) that leads to 
increased expression of kinin receptors (Zhang et al., 2005; Zhang et al., 2004). SP600125, a 
JNK MAPK inhibitor, reduces ozone- (Williams et al., 2007) and allergen- (Nath et al., 
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2005) induced airway inflammation and AHR. MAPK inhibitors have been under clinical 
development for many years for the treatment of corticosteroid-resistant asthma and COPD in 
both oral and inhaled form, showing promising results (Singh et al., 2015). 
 
1.2 OROPHARYNGEAL CANCER 
 
Oral and pharyngeal cancer, grouped together, is the sixth most common cancer in the world. 
About 90% of all oropharyngeal cancers, including tonsillar cancers are squamous cell 
carcinomas. There is wide geographical variation in the incidence of oropharyngeal cancers 
in the world. While the majority of oropharyngeal cancer incidences in Western countries are 
attributed to the rise of local infections with human papillomavirus (HPV), specifically 
HPV16. It should not be forgotten that the majority of the world’s oropharyngeal cancer cases 
are found in developing countries, where smoking and alcohol rates are still high 
(Warnakulasuriya, 2009). Patients with HPV-positive tonsillar cancer, in particular those who 
are also never-smokers, are reported to have significantly better clinical outcome than 
patients with HPV-negative tonsillar cancer. The latter are almost always heavy smokers 
(Ang et al., 2010; Dalianis, 2014; Hong et al., 2013; Maxwell et al., 2010). 
 
1.2.1 Cigarette smoking 
 
Smoking and alcohol are considered traditional risk factor for tonsillar squamous cell 
carcinoma. Smoking is also found to be an important negative prognostic factor for the 
overall survival (Dalianis, 2014; Hong et al., 2013) and disease recurrence (Maxwell et al., 
2010), regardless of HPV status. Patients who smoke during radiotherapy also have a lower 
rate of response (Browman et al., 1993). This suggests that HPV-positive and smoke-induced 
tonsillar squamous cell carcinomas have distinctly different pathogenesis. Hence, tobacco 
smoke exposure is damaging to oral health, stimulating tonsillar squamous cell carcinoma 
development regardless of the pathogenesis. The mechanisms behind this are not fully 
known. 
 
1.2.2 Activin receptor-like kinases 
 
Activin-receptor like kinases (ALK) are receptors for the transforming growth factor-beta 
(TGF-) superfamily. They are involved in several cancer-related cellular processes including 
proliferation, differentiation, adhesion, migration and apoptosis (Graham et al., 2006). 
Among the seven different ALKs found in humans, ALK1 and 5 are possibly the most 
studied in the context of cancer. ALK1 and ALK5 (also termed TGF-βI receptor) have 
antagonizing effects in endothelial cells. While ALK1 promotes growth and proliferation and 
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thereby carcinogenesis, ALK5 inhibits the process (Jonker, 2014). ALK5 conditional 
knockout mice are found to develop spontaneous squamous cell carcinoma (Honjo et al., 
2007). ALK5 expression was found to be decreased in human head and neck squamous cell 
carcinoma tumor cells (Eisma et al., 1996). At the same time, high levels of ALK1 in tumor 
tissue from patients with head and neck squamous cell carcinoma is correlated with advanced 
T classification (greater tumor size), positive N classification (metastasis to nearby lymph 
nodes), advanced TNM stage (faster growing and spreading cancer), and poor prognosis 
(Chien et al., 2013). Inhibitors of ALK1 are currently under clinical trials for the treatment of 
solid tumors (Cunha et al., 2011; Jonker, 2014) . Blockage of ALK1 signaling using an ALK 
ligand trap ALK1-Fc in combination with cisplatin was recently found to inhibit tumor 
growth in murine head and neck cancer models more efficiently than chemotherapy alone 
(Hawinkels et al., 2015). 
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2 AIMS OF THE THESIS 
 
The overall aim of this thesis is to increase the understanding of the mechanisms behind 
cigarette-smoke induced airway hyperreactivity and inflammation.  
Nicotine and LPS are two of the most important components of cigarette smoke. 
Understanding their functions and interactions in in vitro and in vivo murine models, as well 
as in human samples can reveal mechanisms that will allow the development of new 
therapeutic options for cigarette-smoke induced airway diseases. 
 
The specific aims of the thesis are to: 
 
1. Investigate the effects of nicotine exposure on GPCR agonist mediated airway 
contractions in isolated murine tracheal segments and explore the underlying 
mechanisms; 
 
2. Investigate the effects of nicotine exposure on kinin receptor agonist induced airway 
relaxations in isolated murine tracheal segments and explore the underlying 
mechanisms; 
 
3. Investigate the effects of long-term nicotine exposure on cell-surface TLR expression 
in isolated murine tracheal segments and its subsequent effect on LPS-induced AHR; 
 
4. Investigate the effects of long-term nicotine exposure in mouse in vivo on LPS-
induced AHR and explore the underlying mechanisms, with emphasis on neuronal 
mechanisms; 
 
5. Investigate the effect of cigarette smoke exposure on tonsil ALK expression using a 
novel cotinine assay to quantify the level of cigarette smoke exposure in tonsil tissue.  
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3 MATERIAL AND METHODS 
 
3.1 IN VITRO MURINE MODEL 
 
3.1.1 Tissue preparation and organ culture 
 
Organ culture was performed according to previous protocols (Zhang et al., 2004). Tracheae 
from 10-week-old male BALB/c mice were dissected and cut into 4 segments (or 2 segments 
for EFS experiments) and placed individually in wells of a 48-well plate (or 24-well plate for 
EFS experiments; Ultra-low attachment, Sigma, St Louis, MO) with 1 ml serum-free 
Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with penicillin (100 U/ml) 
and streptomycin (100 µg/ml).  
The tracheal rings were incubated for 1, 2 or 4 days at 37°C in humidified 5% CO2 in air in 
the presence of vehicle or nicotine, with/without different concentrations of LPS (0.01, 0.1 
and 1 g/ml), with/without specific MAPK inhibitors (SP600125, U0126 or SB203580). 
Tracheal rings were moved into new wells containing fresh medium with supplements of 
nicotine and/or LPS and/or inhibitors every day.  
The experimental protocol was approved by the Stockholm north animal ethics review board 
(Dnr N153/11) and Malmö-Lund’s animal ethics review board (Dnr M15-09). 
 
3.1.2 Epithelial removal 
 
For the epithelium removal experiments, the epithelium from the whole trachea were 
mechanically scraped away gently by moving a coarse metallic rod in and out of the trachea, 
prior to cutting into segments and organ culture.  
 
3.1.3 In vitro pharmacology 
 
Contractile or relaxant responses of the tracheal segments were measured in temperature-
controlled (37C) myographs (Organ Bath Model 700MO, J.P. Trading, Aarhus, Denmark), 
containing Krebs–Henseleit buffer solution and continuously equilibrated with 5% CO2 and 
95% O2. The tracheal segments were mounted on two L-shaped metal prongs, and gradually 
stretched over the course of one hour to reach a resting tension of 0.8 mN (or 1.6 mN for EFS 
experiments). One prong was connected to a force–displacement transducer for continuous 
recording of isometric tension by the Chart software (ADInstruments Ltd, Hastings, UK). 
The other prong was connected to a displacement device, allowing adjustment of the distance 
between the two parallel prongs. 
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In vitro pharmacology was performed according to previous protocols (Adner et al., 2002; 
Bachar et al., 2005b). The viability of the segments was first tested using 60 mM KCl. KCl 
was later washed out with Kreb-Henseleit buffer solution three times until the segments 
reached basal tension. For contraction studies, each segment was incubated with 3 μM of the 
non-selective COX inhibitor indomethacin for 30 min before administration of agonists to 
inhibit epithelium-dependent relaxations. GPCR agonists such as ET-1, 5-hydroxytryptamine 
(5-HT) and bradykinin were then administered cumulatively to produce their concentration-
effect curves.  
To test relaxant properties, segments were pre-constricted with 1 μM carbachol, and after 
reaching stable plateaus, the concentration-effect curves for bradykinin-, des-Arg
9
-
bradykinin-, isoprenaline- and PGE2-induced relaxations were produced in the absence of 
indomethacin. To further dissect the mechanisms behind the relaxation responses, the 
selective COX-1 inhibitor piroxicam (5 nM), the selective COX-2 inhibitor DuP-697 (5 nM), 
the non-selective COX inhibitor indomethacin (2 µM)  or the selective EP2 inhibitor 
PF04418948 were added 30 min prior to carbachol preconstriction in attempts to inhibit the 
relaxation responses. 
 
3.1.4 Electric field stimulation 
 
Electric field stimulation (EFS) was used to access nerve-induced contractions, and carried 
out according to previous protocols (Bachar et al., 2005a). Tracheal segments were 
stimulated with EFS by two electrodes placed at opposite sides of the tracheal segments 
(Current Stimulator Model CS200, J.P. Trading, Aarhus, Denmark). Each segment was first 
contracted with 60 mM KCl to test its viability. After washing out KCl, and returning to 
resting state, each segment was given five training impulses of 4 Hz, 55 mA (≈10 V). Later, 
segments were given a 2log EFS series of 0.2–12.8 Hz. Each impulse was 0.8 ms long with 
duration of 1 min, followed by 1.5 min rest. Segments were washed and then incubated for 30 
min with 3 μM of the non-selective COX inhibitor indomethacin before EFS, followed by the 
same procedure after incubation with 3 μM indomethacin and 10 µg/ml LPS for 1 hr.  The 
experiment ended with a control contraction to 0.1 μM carbachol. 
 
3.2 IN VIVO MURINE MODEL 
 
3.2.1 Treatment protocol 
 
10-week old female BALB/c mice were implanted with Alzet® osmotic pumps (model 2004, 
Durect Corporation, USA) containing either sterile phosphate-buffered saline (PBS) or PBS-
buffered nicotine tartate salt solution (24 mg/kg/day, Sigma-Aldrich, USA). The mice were 
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then housed for 24 days in groups of four in temperature- and humidity-controlled rooms 
with 12:12 hour light-dark cycle. Standard food and water were provided ad libitum.  At day 
25, the mice started to receive daily intranasal instillations of LPS for 3 consecutive days. At 
day 28, lung mechanics were measured with a flexiVent
TM
 small animal ventilator. 
Bronchoalveolar lavage fluid was obtained. The right lung lobes were fixated in formalin for 
histological analysis and the left lung lobes were snap-frozen in liquid nitrogen for protein 
analysis (Fig 1). 
 
 
Fig 1. In vivo treatment protocol. 
 
Animal procedures were reviewed and approved by the Stockholm north animal ethics 
review board (Dnr N153/11 and N258/13). 
 
3.2.2 Subcutaneous osmotic pump implantation 
 
Mice were anesthetized by continuous inhalation of isoflurane and a small incision was made 
behind the neck using aseptical techniques. A pre-conditioned Alzet
®
 osmotic pump (model 
2004, Durect Corporation, USA) with an infusion rate of 0.25 μl/h , containing either sterile 
phosphate-buffered saline (PBS) or PBS-buffered nicotine tartate salt solution (24 mg/kg/day, 
Sigma-Aldrich, USA) was implanted in a subcutaneous pouch. The incision was closed using 
2-3 sterile Reflex clips (Alzet
®
, USA). Mice were allowed to recover for 30 min before 
returning to home cage. Clips were removed 7-10 days post-operation. 
 
3.2.3 Intranasal LPS instillations 
 
Mice were anesthetized with isoflurane and 20 l of LPS from Escherichia coli 0127:B8 (0.1 
mg/ml, Sigma-Aldrich, USA) or PBS was placed as a big droplet in their nostrils while the 
mice were held in an upright posture. The droplet was sniffed in by the mice reaching their 
lungs. 
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3.2.4 Airway mechanics 
 
Mice were anesthetized with pentobartial sodium (90 mg/kg body weight) and then placed on 
a heating pad (37C). A tracheotomy was performed and a 18-gauge cannula was inserted. 
The mouse was then connected to a flexiVent
TM
 small animal ventilator (Scireq, Montreal, 
Canada). After ventilation was started, bilateral thoracotomy was performed, in order to 
equalize pleural pressure to atmospheric and to exclude chest wall contribution to the 
mechanics. Animals were ventilated at a tidal volume of 12 ml/kg
 
body weight and the 
positive end-expiratory pressure (PEEP) was kept at 3 cm H2O. An i.v. catheter was inserted 
into the tail vein. Acetyl-ß-methylcholine (Mch, Sigma-Aldrich, St Louis, MO, USA) was 
injected through the tail vein in increasing doses (0.01, 0.03, 0.1, 0.3, 1 and 3 mg/kg
 
body 
weight) to induce airway contractions. Nerve blockage was achieved by pretreatment with 
tetrodotoxin (6 g/kg, Tocris Bioscience, United Kingdom) prior to Mch challenge. A 
broadband forced oscillation manoeuvre was carried out and measurements fitted with a 
constant phase model to compute Newtonian resistance (Rn), tissue damping (G) and tissue 
elastance (H) (Bates et al., 2011). 
 
3.2.5 Bronchoalveolar lavage 
 
BAL was collected after airway mechanical measurements by carefully filling the lungs with 
0.7 ml of ice-cold PBS which was withdrawn 3 times with a syringe. The fluid was 
centrifuged at 4°C, 1200 rpm, for 10 minutes and the supernatant was stored at −80°C until 
use. 
Total cell number was counted on Fast Read 102

 plastic counting slides immediately after 
mixing 10 µl cell suspensions with 90 µl Gentiana blue. Differential cell counts were 
performed on May-Grünwald/Giemsa stained cytospin preparations, counting a minimum of 
300 cells, in a blinded manner. 
MMP-9 and TIMP-1 in BAL were measured with ELISA kits (mouse total MMP-9 
Quantikine ELISA kit and mouse TIMP-1 kit Quantikine Immunoassay, R&D systems, 
USA), according to the manufacturers’ instructions. 
 
3.2.6 Histology 
 
Right lung lobes were fixated in formaldehyde, dehydrated, embedded in paraffin and 
sectioned with a microtome. Sections were immersed in UltraClear
TM
 followed by decreasing 
concentrations of ethanol for deparaffinzation and then immersed in deionized water for 
rehydration. The slides were then stained with hematoxylin and eosin (H&E) for morphology 
and semi-quantification of inflammation, or picrosirius red for visualization of collagen.  
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Peribronchial, perivascular and parenchymal inflammatory cell infiltration were semi-
quantitatively graded in a blinded manner as 0 to 3 (0 = no cell infiltration, 3 = abundant) under 
a light microscope (Olympus BX50 microscope with Nikon Digital Sight DS-5M camera) 
under 400x magnification. 
 
3.2.7 Lung homogenate 
 
Left lung lobes were snap-frozen in liquid nitrogen and stored in -80C after lung 
physiological measurements and BAL collection. Upon use, the samples were defrosted and 
washed free of visible blood using ice-cold PBS. Lung homogenate was obtained by adding 
10 µl of PBS to every 1 mg lung tissue and homogenized at 5000 rpm in two 20s cycles 
(Precellys

24, Bertin technologies, USA) with 2.8mm ceramic beads. 
Every 20 µl of lung homogenate were then digested with 80 µl of 0.5M acetic acid and 
pepsin mixture and the amounts of acid- and pepsin soluble collagen were measured with 
Sircol
TM
 collagen assay (Biocolor, UK) according to the manufacturer’s instructions. 
 
3.3 HUMAN TONSILS 
 
Twenty seven pairs of tonsils were collected from patients between 15 and 40 years old 
undergoing bilateral tonsillectomy at the Ear- nose- and throat clinic at Malmö University 
Hospital, Sweden for chronic tonsillitis. Apart from the tonsillar symptoms, all subjects were 
healthy and did not receive any medications. The allergy statuses of the patients were 
determined by blood Phadiatop

 testing for allergen-specific IgE.  
Directly after surgery, tonsils were cut into small pieces. Some pieces (20-40 mg) were 
placed in RNAlater (QIAGEN, Germany) for 24 hrs at room temperature and then kept at 
−80°C until use, while others (50-150 mg) were snap-frozen in liquid nitrogen and then kept 
at −80°C until use. 
The study was approved by the Lund University research ethics committee (Dnr LU 293-03). 
Informed consent was obtained from all participants. 
 
3.3.1 Tonsil cotinine assay 
 
Small pieces of tonsils that were snap-frozen in liquid nitrogen and stored in -80C were 
defrosted in room temperature. Samples were weighed. For every mg of tissue, 3 µl of sterile 
PBS was added. The tissue was then homogenized together with 1.4 mm ceramic beads in a 
Precelleys

24 homogenizer (Bertin Technologies, France) at 5000 rpm for 20 sec x 2. The 
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homogenate was subsequently centrifuged and the supernatant was used for cotinine 
measurements using a Cotinine ELISA kit (Abnova, Taiwan) following the manufacturer’s 
instructions. 
 
3.4 REAL-TIME PCR 
 
3.4.1 RNA extraction 
 
RNA was extracted using RNeasy mini kit (QIAGEN, Germany) according to the 
manufacturer’s instructions. Pieces from tonsils or tracheae were stored in RNAlater 
(QIAGEN, Germany) at -20C or -80C, defrosted, squeezed free of excessive RNAlater, 
weighed and homogenized in a Precelleys

24 homogenizer. RNA was extracted from the 
homogenate using a spin-column based technique (RNeasy Mini Kit, QIAGEN, Germany) 
according to manufacturer’s protocol. RNA quality was accessed using a Nanodrop® ND-
3300 spectrophotometer (Thermo Scientific, USA). A260/A280 ratio and A260/A230 ratio 
over 1.8 were accepted as “pure” RNA. 
 
3.4.2 Reverse transcription 
 
Reverse transcription of RNA (100 ng/µl) into cDNA was carried out using Omniscript™ 
reverse transcriptase kit (QIAGEN, Germany) with oligo(dT)16 primers (DNA Technology 
A/S, Denmark) in a 20 μl reaction volume with a Mastercycler personal PCR machine 
(Eppendorf AG, Germany) at 37 °C for 1 hr according to the manufacturer’s protocol. 
 
3.4.3 Real-time PCR 
 
Both TaqMan
®
 Gene Expression Mastermix (QIAGEN, Germany) and QuantiTect
TM
 SYBR
®
 
Green PCR kit (QIAGEN, Germany) were used for real-time PCR in the present studies.  
Using TaqMan
®
 Gene Expression Mastermix and MicroAmp
®
 fast optical 96-well reaction 
plates (Applied Biosystems, USA) real-time PCR was performed in 20-μl reaction volumes 
according to the manufacturer’s instructions. Each sample was analyzed in duplicate. 
Commercially available Taqman
®
 probes were used (Applied Biosystems, USA). 40 PCR 
thermal cycles were ran in the Applied Biosystems 7500 Real-Time PCR System. β-actin, 
Hprt1 and GAPDH were used as housekeeping genes. 
Using QuantiTect
TM
 SYBR
®
 Green PCR kit (QIAGEN, Germany), real-time PCR was 
performed in the Smart Cycler® II system (Cepheid, Sunnyvale, CA, USA). A reaction 
  23 
volume of 25 l was used and carried out with heating 95°C for 15 min followed by 
touchdown PCR i.e. denature at 94°C for 30 sec and annealing at 66 °C for 1 min for the first 
PCR cycle, thereafter, a 2°C decrease for the annealing temperature in every cycle up to 56°C. 
Finally, 40 thermal cycles with 94°C for 30 sec and 55°C for 1 min were performed. The 
specificity of the PCR products was checked by using the dissociation curves. Primers were 
designed using Prime Express 2.0 software (Applied Biosystem, Forster city, CA, USA) and 
synthesized by DNA Technology A/S (Aarhus, Denmark). GAPDH was used as the 
housekeeping gene. The primer sequences are as below (Table 1): 
 
Table 1: Primer sequences for real-time PCR 
Namn GenBank No Primer sequences (5’-3’) 
mTLR1 NM_030682.1 Fwd: 5’-CAA GCA TTT GGA CCT CTC CTT TA-3’ 
Rev: 5’-GTA CCC GAG AAC CGC TCA AC-3’ 
mTLR2 NM_011905.2 Fwd: 5’-TCA CCA CTG CCC GTA GAT GA-3’ 
Rev: 5’-CAA GAT GTA ACG CAA CAG CTT CA-3’ 
mTLR4 NM_021297.2 Fwd: 5’-GAA CCC TCT ATC ATG GAA GGA CTA TG-3’ 
Rev: 5’-TTC GCC AAG CAA TGG AAC TTA-3’ 
mTLR5 NM_016928.2 Fwd: 5’-CTG GGG ACC CAG TAT GCT AA-3’ 
Rev: 5’-ACA GCC GAA GTT CCA AGA GA-3 
mTLR6 NM_011604.2 Fwd: 5’-ACC TGG AAG TGC TCG GTT AAA C-3’ 
Rev: 5’-TTC CCT GTC GAT TCT CTC AGT TAT C-3’ 
mTLR11 NM_205819.1 Fwd: 5’-TCC TTC CTC TGA TTA GCT GTC CTA A-3’ 
Rev: 5’-TCC ACA TAA TTT CCA CCA ACA AGT-3’ 
mGAPDH 
 
XM_001473623.1 Fwd: 5’-CAT GGC CTT CCG TGT TCC TA-3’ 
Rev: 5’-TGC TTC ACC ACC TTC TTG ATG-3’ 
mCOX-2 NM_011198 Fwd: 5’-CTC CCT GAA GCC GTA CAC AT-3’ 
Rev: 5’-ATG GTG CTC CAA GCT CTA CC-3’ 
mTNF- NM_013693 Fwd: 5’-GAC TCA AAT GGG CTT TCC GA-3’ 
Rev: 5’-TCC AGC CTC ATT CTG AGA CAG AG-3’ 
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mB1R NM_007539 Fwd: 5'-CCA TAG CAG AAA TCT ACC TGG CTA AC-3'; 
Rev: 5'-GCC AGT TGA AAC GGT TCC-3' 
mB2R NM_009747 Fwd: 5'-ATG TTC AAC GTC ACC ACA CAA GTC-3';  
Rev: 5'-TGG ATG GCA TTG AGC CAA C-3' 
 
The relative amounts of mRNA were determined by subtracting the threshold cycle (CT) 
values for these genes with the CT value for the most stable housekeeping gene to obtain the 
ΔCT value and then expressing amount as 2
−ΔCT
 relative to housekeeping gene.  
 
3.5 IMMUNOHISTOCHEMISTRY 
 
3.5.1 Cryosection 
 
After organ culture, the tracheal rings were immersed in a fixative solution consisting of 4% 
paraformaldehyde in 0.1 M phosphate buffer (pH 7.4) for 3 hrs at 4°C. The specimens were 
dehydrated in 20% sucrose with 0.1 M phosphate buffer (pH 7.4) for 24 hrs at 4°C, and then 
frozen in Tissue-Tek

 O.C.T. (Sakura Finetek Europe BV, Netherlands) and stored at -80°C. 
Ten μm-thick sections were cut using a cryostat. These were mounted on SuperFrostTM Plus 
slides (Menzel GMBH & COKG, Germany) and frozen in -20C until staining. 
Immunohistochemistry was performed according to standard protocols, i.e. the sections were 
incubated with the primary antibody overnight at 4°C and the secondary antibody for 1 hr at 
room temperature in the dark. In the control experiments, either the primary antibody or the 
secondary antibody was omitted. 
 
3.5.2 Paraffin-embedded tissue 
 
Tracheal segments or lung tissue were immersed in a fixative solution consisting of 
phosphate-buffered formaldehyde overnight at 4°C. The tissues were dehydrated in series of 
ethanol from 50% to 99.5%, followed by UltraClear
TM
 and embedded in paraffin blocks. 
Sections were cut into 4 μm-thick slices using a microtome and mounted on SuperFrostTM 
Plus slides (Menzel GMBH & COKG, Germany). 
Sections were then deparaffinized, rehydrated and underwent target retrieval in 98C citrate 
buffer for 25 min prior to immunohistochemical staining.  The sections were permeabilized 
with 1% Triton-X100, blocked with 10% donkey serum in 1% bovine serum albumin (BSA) 
  25 
and then incubated with the primary antibody overnight in 4C in darkness. The sections 
were then incubated with the secondary antibody (raised in donkey) for 1 hr in room 
temperature in darkness. Appropriate IgG isotype controls were used instead of the primary 
antibody as control for non-specific staining. 
 
3.5.3 Confocal microscopy 
 
The stained specimens were examined under a confocal microscope (Leica, Wetzlar, 
Germany or Nikon, C1plus, Nikon Instruments Inc., NY, USA) for semi-quantification of 
protein expressions. The fluorescence intensity was measured and analyzed by Image J 
software (http://rsb.info.nih.gov/ij). Either the entire preparation or 6 randomly selected 
sections were measured. All experiments were carried out in one single batch and 
measurements were done under the same microscope instrument setting on the same day to 
ensure comparability between the slides. 
 
3.6 STATISTICS 
 
All data were expressed as mean values ± S.E.M. Agonist concentration-effect curve data 
from individual segments were fitted to the Hill equation using an iterative, least-squares 
method (GraphPad Prism

 5, U.S.A.) to provide estimates of maximal contraction (Emax) and 
pEC50 (negative logarithm of the agonist concentration that produces half of its maximal 
effect). Concentration-effect curves obtained from the in vitro pharmacology experiments 
were compared using two-way analysis of variance (ANOVA). Unpaired two-tailed Student’s 
t-test was used when two groups are compared to each other. One-way ANOVA were 
performed when three or more groups are compared with each other. Bonferroni’s post hoc 
analysis was used to correct for multiple comparisons. Linear regression was used to 
determine correlation between data. P-values less than 0.05 were considered to be statistically 
significant. 
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4 RESULTS AND COMMENTS 
 
4.1 NICOTINE ON AIRWAY SMOOTH MUSCLE CONTRACTION (PAPER I) 
 
4.1.1 Time- and concentration-effect 
 
Murine tracheal segments were cultured for one (Fig. 2A-B), two (Fig. 2C-D) or four (Fig. 
2E-F) days in serum-free DMEM medium in presence of nicotine (1 and 10 μM) or vehicle 
(DMSO). Contractile responses monitored with myographs were induced by the following 
GPCR agonists: the kinin B1 receptor agonist des-Arg
9
-bradykinin (D-A-BK, Fig 2A,C,E), 
the B2 receptor agonist bradykinin (BK, Fig 2B,D,F), the 5-HT receptor agonist 5-HT, the 
cholinergic agonist acetylcholine, the non-selective ET receptor agonist ET-1 and the 
selective ETB receptor agonist sarafotoxin 6c.  
The results showed that nicotine did not affect the contractile responses mediated by 5-HT, 
cholinergic or ET receptors (data not shown). For kinin receptor agonists, a tendency towards 
an increased airway contractile response to des-Arg
9
-bradykinin and bradykinin was seen 
already after 2 days of nicotine treatment (Fig. 2C-D) and this increase reached statistical 
significance at day 4 (Fig. 2E-F). After 4 days of organ culture with a lower nicotine 
concentration (1 μM), the contractile responses to des-Arg9-bradykinin and bradykinin were 
not significantly altered, while culture with 10 μM of nicotine significantly increased the Emax 
for both agonists (Fig. 2E-F). Although a tendency towards an increased pEC50 could be seen, 
it did not reach statistical significance (des-Arg
9
-bradykinin: Ctrl 6.96 ± 0.17, 10 μM nicotine 
7.20 ± 0.20, p>0.05; bradykinin: Ctrl 6.72 ± 0.38, 10 μM nicotine 7.30 ± 0.25, p>0.05). Two 
different neuronal nicotinic receptor antagonists MG624 and hexamethonium both blocked 
the nicotine-induced effects (data not shown). 
 
4.1.2 Transcriptional upregulation of kinin receptors 
 
The relative amount of mRNA for kinin B1 and B2 receptors was semi-quantified by real-time 
PCR, and their corresponding protein expression with immunohistochemistry. Four days of 
organ culture in the presence of nicotine (10 μM) increased the mRNA expression for both 
receptors, compared to controls (Fig. 3A). An increase in kinin B1 (Fig. 4A,B,E) and B2 (Fig. 
4C,D,F) receptor protein expressions was seen in both the airway epithelial and smooth 
muscle cells (Fig. 4E-F). After nicotine treatment, the increase in B1 receptor protein 
expression was more prominent in the smooth muscle cells than in the epithelial cells (Fig. 
4E), while the increase of B2 receptors was more prominent in the epithelial cells (Fig. 4F). 
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Figure 2. Time- and concentration-dependent effects of nicotine (Nic) on contractions of 
murine tracheal segments induced by des-Arg
9
-bradykinin (D-A-BK; A, C, E) or 
bradykinin (BK; B, D, F). Each data point is derived from 15-22 experiments and data is 
presented as mean ± S.E.M. Statistical analysis was performed using two-way ANOVA 
Bonferroni's post hoc analysis. Control vs Nic. * P < 0.05; ** P < 0.01; *** P < 0.001. 
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Figure 4. Nicotine (Nic) 
effects on kinin B1 (B1R) 
and B2 (B2R) receptor 
protein expressions. The 
reference bar corresponds 
to 25 μm. Epi = 
epithelium; SMC = 
smooth muscle cells; and 
C = cartilage. Each data 
point is derived from 6 
experiments. Two-tailed 
unpaired Student's t-test 
with Welch's correction 
was performed. Control 
vs Nic * P < 0.05; *** P 
< 0.001. 
Figure 3. Kinin B1 (B1R) and B2 (B2R) receptor mRNA expressions. Each data point is 
derived from 3-6 experiments and data is presented as mean ± S.E.M. Statistical analysis 
was performed using unpaired Student's t-test with Welch's correction. Control vs Nic 
(A); Nic vs Nic+SP600125/YM976 (B). ** P < 0.01; *** P < 0.001. 
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4.1.3 Involvement of JNK and PDE4 pathways 
 
Confocal-microscopy-based immunohistochemistry showed that 4 days of nicotine treatment 
induced activation (phosphorylation) of JNK (Fig. 5), but not ERK1/2 and p38 (data not 
shown). Inhibition of JNK with its specific inhibitor SP600125 abolished the nicotine-
induced effects on kinin receptor-mediated contractions (Fig. 6A-B) and reversed the 
enhanced receptor mRNA expressions (Fig. 3B).  
Similar effects were observed after administration of the specific PDE4 inhibitor YM976. 
YM976 decreased the nicotine-enhanced kinin receptor mRNA expressions (Fig. 3B), as well 
as the airway contractile responses to des-Arg
9
-bradykinin and bradykinin (Fig. 6C-D).  
 
 
 
4.1.4 Comments 
 
The present study demonstrated that long-term exposure (4 days) of mouse tracheal segments 
to nicotine caused a concentration-dependent increase of kinin B1 and B2 receptor-mediated 
airway contractions. Short-term nicotine exposure (1-2 days) induced no significant effects. 
Nicotine treatment did not affect airway contractions mediated by 5-HT, cholinergic or 
endothelin receptors. The increase in Emax, without significant change of pEC50, seen after 4 
days of nicotine treatment suggested an increase in kinin receptor protein expression rather 
than alteration of receptor sensitivity. This conclusion was further supported by the discovery 
of upregulated protein expressions for both B1 and B2 receptors using immunohistochemistry. 
In addition, real-time PCR revealed a parallel increase in B1 and B2 receptor mRNA 
suggesting the involvement of transcriptional mechanisms in the effects of nicotine. The 
Figure 5.  Nicotine (Nic) effects on phosphorylated JNK (pJNK) protein expressions. 
The reference bar corresponds to 25 μm. Epi = epithelium; SMC = smooth muscle cells; 
and C = cartilage. Each data point is derived from 6 experiments. Two-tailed unpaired 
Student's t-test with Welch's correction was performed. Control vs Nic. ** P < 0.01; *** 
P < 0.001. 
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intracellular cascades involved in the kinin receptor upregulation seemed to be both JNK- and 
PDE4-related intracellular signal pathways. 
 
 
Many GPCRs are involved in the regulation of the contractile state of airway smooth muscle. 
Bradykinin, ET and M3 muscarinic receptors are Gq-coupled while 5-HT receptors are Gi-
coupled (Billington et al., 2003). Our results showed that nicotine upregulated kinin B1 and 
B2 receptor-mediated airway contractions, leaving 5-HT, cholinergic and ET receptor-
mediated contractions unaffected. This suggested that nicotine acted on specific targets 
within the airways. Thus, the effects observed were neither the result of a general hyperres-
Figure 6. Effects of JNK inhibitor SP600125 (10 μM, A, B) and YM976 (YM, 1 μM, C, 
D) on nicotine-enhanced des-Arg9-bradykinin- (A, C) and bradykinin- (B, D) induced 
contractions. Each data point is derived from 4-17 experiments and presented as mean ± 
S.E.M. Statistical analysis was performed using two-way ANOVA with Bonferroni's 
post hoc analysis. Nic+vehicle vs Nic+inhibitor. * P < 0.05; ** P < 0.01; *** P < 0.001. 
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ponsiveness nor due to alteration of downstream G-protein signaling processes. This idea was 
further strengthened by the finding of a simultaneous upregulation of kinin receptor function, 
mRNA and protein expression, revealing a special role for bradykinin in nicotine- and/or 
tobacco smoke-induced AHR. 
JNK has long been implicated in the pathogenesis of asthma (Adcock et al., 2004). In a study 
of human bronchial epithelial cells, ERK1/2, JNK, but not p38 was strongly activated after 
treatment with nicotine (Tsai et al., 2006). In the present study, nicotine induced phosphory-
lation of JNK, but not ERK1/2 and p38. SP600125, a small molecular inhibitor for JNK, 
abolished the nicotine-enhanced kinin receptor-mediated contractions and the receptor 
mRNA expression. These results are well in line with a previous study which has demon-
strated that SP600125 exhibits a powerful inhibitory effect on TNF-α induced upregulation of 
kinin B1 and B2 receptors in airways (Zhang et al., 2004). SP600125 was applied at a 
concentration of 10 μM.  At this concentration, SP600125 was found to selectively inhibit the 
phosphorylation of JNK, but not ERK1/2 or p38 in blood vessels (Xu et al., 2008). SP600125 
up to 30 μM caused no alteration in carbachol-elicited contractile responses in isolated airway 
segments (Zhang et al., 2004). 
YM976 is a selective PDE4 inhibitor shown to possess powerful anti-inflammatory and direct 
bronchorelaxatory effects (Aoki et al., 2000). PDE4 is expressed in airway smooth muscle 
cells and increases intracellular concentration of the second messenger cAMP (Torphy et al., 
1993). A previous study has shown that inhibition of PDE4 suppresses endotoxin-induced 
airway inflammation and hyperreactivity (Toward et al., 2001). Our results showed that 
YM976 attenuated the nicotine-enhanced kinin B1 and B2 receptor-mediated airway 
contractions. Inhibition of PDE4 produces a specific depression of nicotine's effects without 
altering control, suggesting that the nicotine-induced changes might be PDE4-specific.  
The present study showed the simultaneous involvement of both JNK and PDE4/cAMP-
mediated pathways in the effects of nicotine on kinin receptors. Supporting this, there have 
been several reports on the cross-talk between cAMP and JNK pathways. For example, 
cAMP has been shown to inhibit JNK activation in human airway smooth muscle cells (Kaur 
et al., 2008) and lung cancer cells (Park et al., 2016). cAMP specifically blocked activation 
of JNK, but not ERK 1/2 through protein kinase A (Pearson et al., 2006). 
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4.2 NICOTINE ON AIRWAY EPITHELIAL RELAXATION (PAPERS I & II) 
 
4.2.1 Short-term nicotine exposure 
 
Relaxation responses to bradykinin, des-Arg
9
-bradykinin, PGE2, and isoprenaline were 
studied in fresh murine tracheal segments or segments after 1 day of organ culture 
with/without nicotine (Fig. 7). Pre-contraction was induced by 1 M of carbachol. Pre-
contraction levels were similar in all groups (data not shown). 
 
 
Figure 7.  One-day nicotine exposure on airway relaxations. Cumulative dose–
response relaxation curves to des-Arg
9
-bradykinin (A), bradykinin (B), PGE2 (C) and 
isoprenaline (D) were performed after pre-contraction with 1 μM carbachol. Each data 
point was derived from 7 to 18 segments. Statistical analysis was performed using two-
way ANOVA with Bonferroni's post-hoc analysis. Culture vs Nic; *** P < 0.001. 
Culture vs Fresh. 
+
 P < 0.05; 
++
 P < 0.01; 
+++
 P < 0.001. 
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Fresh segments barely responded to des-Arg
9
-bradykinin (6.3 ± 2.0% relaxation, at 10
− 6
 M of 
agonist, Fig. 7A), exhibited limited relaxation to bradykinin (24.4 ± 3.9% relaxation, at 10
− 6
 
M of agonist, Fig. 7B), but relaxed markedly in response to PGE2 (64.2 ± 3.9% relaxation, at 
10
− 6
 M of agonist, Fig. 7C) and isoprenaline (50.7 ± 3.8% relaxation, at 10
− 6
 M of agonist, 
Fig. 7D). The organ culture procedure per se greatly increased the relaxation response to 
bradykinin and des-Arg
9
-bradykinin (Fig. 7A-B), modestly affected isoprenaline relaxations 
(Fig. 7D) and did not alter relaxations induced by PGE2 (Fig. 7C). 
Nicotine suppressed the organ-culture-enhanced relaxations induced by des-Arg
9
-bradykinin 
and bradykinin, leaving PGE2- and isoprenaline-induced relaxations unaltered (Figs. 7A–D). 
Nicotine by itself produced nearly negligible relaxations regardless of group (Fresh: 9.3 ± 3.7% 
relaxation, n = 5; Organ culture: 6.4 ± 1.5% relaxation, n = 7; Nic: 7.3 ± 2.3% relaxation, n = 
4, at 10
− 6
 M of agonist). 
 
4.2.2 Long-term nicotine exposure 
 
Murine tracheal segments were cultured for 4 days in serum-free DMEM medium in the 
presence of nicotine (10 μM) or vehicle (0.1% DMSO). Their relaxation responses to 
bradykinin and des-Arg
9
-bradykinin were characterized after pre-contraction with 1 M 
carbachol in the absence of COX inhibitors. Neither B1 nor B2 receptor-mediated relaxations 
were affected by long-term nicotine exposure in vitro (Fig. 8). 
 
 
Figure 8.  Four-day nicotine exposure on kinin receptor-mediated airway relaxations. 
Each data point is derived from 6-8 experiments and data is presented as mean ± S.E.M. 
Statistical analysis was performed using two-way ANOVA with Bonferroni's post hoc 
analysis. Control vs Nic. No significant differences were found. 
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4.2.3 Role of epithelium 
 
The epithelial layers of the tracheal segments were gently scraped away prior to organ culture 
with vehicle (0.1% DMSO) or nicotine (10 μM) for one day. This process nearly completely 
abolished des-Arg
9
-bradykinin- (Fig. 9A) and bradykinin- (Fig. 9B) induced relaxations in 
both organ cultured and nicotine-treated segments which shows that kinin-receptor mediated 
relaxations are epithelium-dependent. 
 
 
 
4.2.4 Involvement of COX pathways 
 
Kinin receptor agonist induced airway relaxations are dependent on the airway epithelium as 
well as on COX activity and EP receptors (Barnes, 1992). To further dissect the underlying 
mechanisms, segments were treated with indomethacin (2 μM), DuP-697 (selective COX-2 
inhibitor, 5 nM), piroxicam (selective COX-1 inhibitor, 5 nM) or PF04418948 (selective EP2 
receptor inhibitor, 10 nM) for 30 min in the organ bath. Relaxations were then induced by 
des-Arg
9
-bradykinin or bradykinin after pre-contraction with 1 μM carbachol (Fig. 10). 
The levels of COX-1, COX-2 and microsomal prostaglandin E synthase-1 (mPGES-1) 
mRNA and protein expressions were examined after 1-day organ culture with/without 
nicotine exposure. COX-1, COX-2 and mPGES-1 were upregulated after 1-day of organ 
culture compared to fresh trachea (Fig. 11). 
The increase in COX-2 mRNA expression following organ culture was the most prominent 
(Fig. 11, Fresh: 0.022 ± 0.004, n = 5; Organ culture: 2.31 ± 0.53, n = 5, relative to house-
keeping gene Hprt1). Staining for COX-2 protein with immunohistochemistry revealed that 
Figure 9.  Effect of mechanical epithelial removal on kinin-receptor mediated airway 
relaxations. Each data point was derived from 3 to 5 segments. All data were 
presented as mean ± S.E.M. 
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COX-2 protein was mostly amplified on the smooth muscle, but not on the epithelium (data 
not shown). Nicotine also showed a tendency to decrease organ-culture-induced COX-2, but 
without reaching statistical significance on mRNA (Fig. 11, Organ culture: 2.3 ± 0.5, n = 5; 
Nic: 1.5 ± 0.3, n = 5; P > 0.05, relative to house-keeping gene Hprt1) and protein levels (data 
not shown). 
 
 
 
 
 
 
Figure 10.  Effects of COX- and EP2 receptor inhibition on airway relaxations. Typical 
relaxation trace after each inhibitor is presented. Arrows denote when the first dose of 
relaxation agent is added. Each experiment is carried out individually and repeated 3–6 
times with similar results. 
Figure 11. Effects of organ 
culture, nicotine (Nic) and 
dexamethasone (Dex) on 
mRNA expressions. Each data 
point is derived from 3 to 8 
segments and data is presented 
as mean ± S.E.M. Statistical 
analysis was performed using 
unpaired Student's t-test. Fresh 
vs Organ culture, Organ 
culture vs Nic 10 μM, Organ 
culture vs Dex 1 μM; * P < 
0.05; ** P < 0.01; *** P < 
0.001. 
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Figure 12.  Effects of organ culture, nicotine (Nic) and dexamethasone on mPGES-1 
protein expressions. Epi = epithelium; SM = smooth muscle; and Cart = cartilage. 
Each data point is derived from 3 to 4 samples. One-way ANOVA with Bonferroni's 
post-hoc analysis is performed. * P < 0.05; ** P < 0.01; *** P < 0.001, ns = no 
significance. 
  37 
COX-1 mRNA expression increased 2 folds following organ culture (Fig. 11, Fresh: 0.12 ± 
0.02, n = 7; Organ culture: 0.22 ± 0.02, n = 8, relative to house-keeping gene Hprt1). 
However, despite the changes in mRNA expressions (Fig. 11), COX-1 protein expressions 
were unaltered between groups (data not shown).  
Fresh segments expressed relatively low levels of mPGES-1 protein (Fig. 12A) on the 
epithelium, and the smooth muscle. Organ culture markedly increased the mPGES-1 
expression on both the epithelium (Fig. 12C) and the smooth muscle (Fig. 12B). Nicotine 
significantly decreased the mPGES-1 mRNA expression (Fig. 11, Organ culture: 0.86 ± 0.06, 
n = 6; Nic: 0.64 ± 0.06, n = 6; P < 0.05, relative to house-keeping gene Hprt1) as well as 
protein expression on the smooth muscle (Fig. 12B), and showed a tendency to decrease on 
the epithelium (Fig. 12C).  
 
4.2.5 Comments 
 
In contrast to long-term nicotine induced increase in ASM contractility, short-term nicotine 
induced decrease in epithelium-dependent airway relaxation was not mediated by changes in 
the kinin receptor expression, but rather on changes in the downstream mediators. The 
decreased kinin-receptor-mediated relaxation induced by nicotine was paralleled by 
decreased mPGES-1 mRNA and protein expressions, leaving kinin B1, B2 and COX-1 
mRNA unaltered. A tendency towards a decrease in COX-2 mRNA and protein expressions 
were seen, but it did not reach statistical significance. Neither PGE2- nor isoprenaline-induced 
relaxations were affected by nicotine exposure, suggesting that the downstream EP-receptor 
sensitivity and the relaxation-machinery of the tracheal rings were intact. It is therefore most 
likely that the decreased relaxation was caused by a decrease in PGE2 production. 
Bradykinin and des-Arg
9
-bradykinin cause airway relaxations via stimulation of the kinin B2 
and B1 receptors respectively, with subsequent activation of COX-pathways and production 
of airway relaxing prostaglandins (Barnes, 1992; Li et al., 1998). In our study, selective 
inhibition of COX-2 with DuP-697 and non-selective inhibition of COX-1 and COX-2 with 
indomethacin completely abolished the relaxation induced by des-Arg
9
-bradykinin and 
bradykinin, without affecting PGE2 relaxations. COX-1 inhibition with the selective inhibitor 
piroxicam at previously shown effective concentrations (Bachar et al., 2005b) did not affect 
bradykinin and des-Arg
9
-bradykinin-induced relaxations. The central role of COX-2 in our 
model agrees well with reports indicating that in human (Daham et al., 2011) and guinea pig 
(Safholm et al., 2013) PGE2 is mainly produced by COX-2 and not COX-1. However, 
increases in PGE2 are not always accompanied by increased COX-2 (Kuroda et al., 2003). 
mPGES-1 is an inducible enzyme that is often upregulated, at both mRNA and protein levels, 
simultaneously with COX-2 to increase PGE2 biosynthesis under inflammatory conditions, 
and this upregulation can be abolished by dexamethasone (Murakami et al., 2000). PGE2 
stimulates EP1 receptors that mediate Ca
2+
 mobilization, EP3 receptors that inhibit adenylate 
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cyclase, and EP2 and EP4 receptors that activate adenylate cyclase (Sugimoto et al., 2007). 
Previous studies show that the EP2 subtype is mainly responsible for smooth muscle 
relaxation (Tilley et al., 2003). However, though often upregulated simultaneously, the 
kinetics for the induction of COX-2 and mPGES-1 expressions have been shown to be 
distinct (Stichtenoth et al., 2001), suggesting different transcriptional regulation mechanisms. 
This is in line with our observations that nicotine significantly inhibited mPGES-1 mRNA 
and protein expressions, but only showed a tendency to decrease COX-2. 
It is worth noting that the effect of nicotine on murine airway relaxations is transient. After 4 
days of organ culture, the difference between nicotine-treated and control segments 
disappears. At the same time, the morphology of the relaxation curve is drastically altered. 
While the relaxation curve after 1 day of organ culture has an inverse S-shape, the relaxation 
curve to bradykinin and des-Arg
9
-bradykinin becomes more or less a straight line. 
Histological studies of cultured guinea pig bronchi showed that long-term organ culture (3 
days or longer) caused submucosal swelling and decreased epithelial integrity, while the 
smooth muscle layer was unaffected. In situ detection of apoptosis by TUNEL assay and 
DAPI counterstaining revealed increases in apoptosis with time in the epithelial and 
submucosal layers, but not in the smooth muscle (Morin et al., 2005). These findings suggest 
that normal epithelial, but not smooth muscle function is disrupted by long-term organ culture, 
making the long-term organ culture model unsuitable for studies of epithelial function.  
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4.3 NICOTINE ON NERVE-MEDIATED AIRWAY CONTRACTIONS (PAPER IV) 
 
4.3.1 In vitro effects 
 
Tracheal segments from mice were organ-cultured with nicotine for 1 or 4 days. Their 
contractile responses to increasing frequencies of EFS were recorded before and after 1 hr 
incubation with LPS. Nicotine per se did not have an effect on EFS-induced contractions 
neither after short- nor long-term exposure (Fig. 13).  
LPS increased the contractile responses to EFS after 4 days regardless of nicotine exposure 
(Fig. 13B). The increases were most pronounced at the higher frequencies (~1.5-1.9 fold). 
However, nicotine-treated segments generally displayed lower contractile responses after 
LPS treatment than non-nicotine-treated ones (Fig. 13B).  Responses to KCl and carbachol 
were similar in all groups (data not shown). 
 
 
 
 
 
Figure 13. Effect of 1- and 
4-days nicotine exposure in 
vitro on EFS-elicited airway 
contractions. Tracheal 
segments were cultured for 
1 (A) or 4 (B) days with 
nicotine and pretreated with 
LPS for 1 hr prior to 
stimulation with EFS (0.2–
12.8Hz) in the organ bath. 
Two-way ANOVA with 
Bonferroni post hoc 
analysis (unpaired) was 
used to compare Control vs 
Nicotine, and Control after 
LPS vs Nicotine after LPS. 
Two-way ANOVA with 
Bonferroni’s post hoc 
analysis (paired) was used 
to compare Control vs 
Control after LPS and 
Nicotine vs Nicotine after 
LPS. * p<0.05, ** p<0.01. 
n = 10–12 rings per group. 
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4.3.2 In vivo effects 
 
Long-term (28 days) exposure to nicotine (24 mg/kg/day) delivered via a subcutaneous pump 
did not alter the airway mechanics per se, neither at baseline nor after methacholine (Mch) 
challenge. However, nicotine-treated mice that received intranasal LPS instillations displayed 
reduced responses to Mch in both central (Newtonian resistance, Rn, Fig. 14A) and 
peripheral (tissue damping, G, Fig. 14B) airways.  
 
  
 
Intranasal instillation of LPS (20 l, 0.1 mg/ml) during three consecutive days enhanced the 
concentration-dependent increase in airway resistance caused by intravenous Mch in both 
central (Newtonian resistance, Rn, Fig 14A) and peripheral airways (tissue damping, G, Fig 
14B). The LPS installations also raised the baseline tissue elastance (H, Fig 14C). The 
Figure 14. Airway mechanics after long-term in vivo nicotine exposure. One-way 
ANOVA with Bonferroni’s post hoc analysis was performed for each individual 
methacholine dose. PBS pump LPS i.n. vs Nic pump LPS i.n, * p<0.05, ** p<0.01, 
*** p<0.001; PBS pump PBS i.n. vs PBS pump LPS i.n., 
#
 p<0.05, 
##
 p<0.01, 
###
 
p<0.001. n = 8–12 animals per group. 
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increased AHR could partially be inhibited by intravenous pretreatment with the neurotoxin 
tetradotoxin (6 g/kg) prior to Mch administration (data not shown). 
 
4.3.3 Comments 
 
The present study confirms that intranasal instillations of LPS enhance the concentration-
dependent increase in airway resistance caused by intravenous Mch injections (Starkhammar 
et al., 2012). We have demonstrated that long-term treatment with nicotine did not enhance 
the airway resistance per se, but markedly dampened the expected increase in airway 
resistance after acute LPS. These experiments were reproduced under in vitro conditions, 
using isolated murine tracheal segments. LPS caused a similar increase of the airway 
contractile response induced by EFS. Long-term, but not short-term culture of isolated 
tracheal segments with nicotine, dampened the LPS induced augmentation of the contractile 
EFS response, similar to what was seen for Mch in vivo.  
The striking similarity between the in vivo effects of nicotine and LPS on the Mch-elicited 
AHR and the in vitro EFS-elicited AHR implicates the involvement of nerves in the former. 
EFS contractions in mice are known to be abolished by both the Na
+
 channel blocker 
tetrodotoxin and the cholinergic antagonist atropine (Bachar et al., 2005a) suggesting that this 
response is related to cholinergic nerve activity. The involvement of nerves in in vivo Mch-
induced airway contractions is confirmed by a suppression of Newtonian resistance following 
acute treatment with tetrodotoxin. Other studies have suggested that activation of the transient 
receptor potential vanilloid type 1 (TRPV1) on sensory nerve contributes in this type of LPS-
induced AHR in human bronchi (Calzetta et al., 2015). Bilaterally vagotomized sheep do not 
exhibit any contractile response to Mch suggesting that neuronal mechanisms play a major 
role in this type of smooth muscle contraction in vivo (Wagner et al., 1999). 
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4.4 COMBINED NICOTINE AND LPS ON AIRWAY CONTRACTIONS (PAPER III) 
 
4.4.1 Effects of LPS 
 
Trachea rings were cultured for 4 days in the presence of LPS at concentrations of 10
−5
, 10
−4
, 
and 10
−3
 mg/ml. LPS induced dose-dependent AHR to des-Arg
9
-bradykinin (Fig. 15A) and 
bradykinin (Fig. 15B). LPS at 10
−5
 mg/ml had almost no effect, while 10
-4
 mg/ml and 10
-3
 
mg/ml produced significant effects. The highest effect was reached with 10
−3
 mg/ml LPS for 
both bradykinin and des-Arg
9
-bradykinin. 
 
 
 
4.4.2 Effects of nicotine and LPS combined 
 
Trachea rings were cultured for 4 days with LPS 10
−5
 mg/ml (Fig. 16A-B) or 10
−4
 mg/ml (Fig. 
16C-D) with 10 μM nicotine or vehicle (DMSO). LPS at 10−5 mg/ml alone produced nearly 
no effect on bradykinin- and des-Arg
9
-bradykinin–induced airway contractions, whereas the 
addition of nicotine increased the contractile responses to bradykinin (Fig. 16B) and des-
Arg
9
-bradykinin (Fig. 16A) but not carbachol and KCl (data not shown). Nicotine at 10
−5
 M 
per se also could increase the contractile response, but the magnitude was smaller than when 
nicotine and a low-concentration LPS were combined (Fig. 16). 
A similar synergistic effect between nicotine and LPS was observed at an LPS concentration 
of 10
−4
 mg/ml. Although nicotine alone increased contractions produced by 10
−6
 M des-Arg
9
-
bradykinin by 74% (compared with control contractions) and LPS (10
−4
 mg/ml) increased it 
Figure 15.  Concentration-dependent effects of LPS on kinin receptor agonist 
mediated airway contractions. D-A-BK: des-Arg
9
-bradykinin. BK: bradykinin. Each 
data point was derived from 6 to 11 segments. All data were presented as mean ± 
SEM, LPS-treated versus control (Ctrl). P values were calculated using two-way 
ANOVA with Bonferroni’s post hoc analysis. **P < 0.01; ***P < 0.001. 
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by 80%, the combination of nicotine and LPS increased the contraction induced by 10
−6
 M 
des-Arg
9
-bradykinin by 235% (Fig. 16C).  
 
 
 
 
Nicotine alone increased the contraction produced by 10
−6
 M bradykinin by 109%, whereas 
LPS (10
−4 
mg/ml) alone increased the contraction by 268%. The combination of nicotine and 
LPS increased the contraction by 541%, thereby demonstrating a synergistic effect (Fig. 16D). 
However, when LPS concentration was as high as 10
−3
 mg/ml, the addition of nicotine failed 
to produce a further increase in contraction (data not shown). 
 
4.4.3 Comments 
 
In the present study, nicotine was used to mimic the effects of cigarette smoke exposure, and 
the presence of LPS mimicked bacterial infection. LPS was found to concentration-
Figure 16.  Effects of combined nicotine and LPS exposure on kinin receptor agonist 
mediated airway contractions. Each data point was derived from 5 to 7 segments. All 
data were presented as mean ± SEM, Nicotine+LPS versus Nicotine. P values were 
calculated using two-way ANOVA with Bonferroni’s post hoc analysis. *P < 0.05; **P 
< 0.01; ***P < 0.001. 
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dependently increase the contractile responses to the selective kinin B2 and B1 receptor 
agonists bradykinin and des-Arg
9
-bradykinin without affecting carbachol- or KCl-induced 
contractions. Nicotine exaggerated the AHR to LPS, causing stronger contractions at lower 
concentrations. No such effects were seen when nicotine and LPS were given separately. This 
finding is in agreement with the clinical observation that smokers, regardless of whether they 
have COPD, are more sensitive to bacterial infections than non-smokers (Nikota et al., 2012). 
The current study confirms this idea by demonstrating that nicotine, in combination with low 
concentrations of LPS, induces a more potent response to kinin receptor agonists than the 
sum of the effects of the two substances given separately. In humans, inhalation of 5 g of 
LPS is sufficient to induce a small but significant change in FEV1 in “healthy” smokers (Aul 
et al., 2012), while healthy non-smokers only display a small but not significant decrease in 
FEV1 after 50 μg LPS (Michel et al., 1997). In small animal in vivo experiments, LPS 
administered locally at 10
-1
 mg/ml elicit pulmonary inflammation and AHR (Starkhammar et 
al., 2012). It is therefore important to note that nicotine enhances the response to LPS at 
concentrations more than 1,000-fold lower than that used in vivo. Hence, it is natural to 
assume that the high LPS concentrations produce contractions that are so strong (i.e., close to 
the segment’s contraction maximal limit) that the effect induced by nicotine becomes hard to 
visualize.  
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4.5 NICOTINE ON TLR EXPRESSIONS (PAPERS III AND IV) 
 
4.5.1 mRNA 
 
The effects of nicotine on mRNA expressions of cell surface TLR in mice tracheal segments 
were examined under in vitro conditions. Four days of nicotine exposure (10 μM) increased 
the mRNA expression of TLR2 (1.5-fold; P < 0.05), TLR4 (1.8-fold; P < 0.01), and TLR6 
(2.0-fold; P < 0.01) in the airways. TLR1 and -11 remained unchanged, whereas the mRNA 
expression for TLR5 decreased (−2.4-fold; P < 0.01) (Fig. 17A).  
 
 
 
 
4.5.2 Proteins 
 
After 4 days of organ culture with nicotine in vitro, immunohistochemistry revealed a 
dominating TLR4 staining of the smooth muscle cells during control conditions, with only a 
weak expression in the epithelium. Nicotine exposure increased the TLR4 expression at 
muscular and epithelial levels, with a more prominent increase in the latter (Fig. 18A-C). 
TLR6 staining was evenly divided between the smooth muscle and the epithelium at fresh 
state and increased in both the epithelium and smooth muscle after incubation with nicotine 
(Fig. 18D-F).  
After 28 days of nicotine exposure via a subcutaneous nicotine pump in vivo, the fluorescence 
intensity, which reflects the amount of TLR4 on bronchial epithelial cells, was markedly 
increased compared to mice receiving PBS in their pumps (2.9 fold, p<0.01, Fig. 19A,B,D). 
Figure 17. Effects of nicotine 
on cell surface TLR mRNA 
expressions. Tracheae were 
incubated in the presence of 
vehicle (DMSO, control) or 
nicotine (10 μM) for 4 days. 
Each data point is derived from 
three or four animals. P values 
were calculated using two-
tailed unpaired Student’s t test. 
*P < 0.05; **P < 0.01.  
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Figure 18.  Effects of nicotine on TLR4 (A–C) and TLR6 (D–F) receptor protein 
expressions in isolated mouse airway. C, cartilage; Epi, epithelium; SMC, smooth muscle 
cells. Each data point is derived from 6 experiments. P values were calculated using two-
tailed unpaired Student’s t test, Control versus Nic. *** P < 0.001. 
Figure 19.  TLR4 expressions after long-term in vivo nicotine exposure. A: PBS pump 
PBS i.n.; B: Nic pump; C: Isotype control; D: TLR4 expression semi-quantified by 
florescence intensity. One-way ANOVA with Bonferroni post hoc analysis. PBS pump 
PBS i.n. vs  Nic pump PBS i.n., *** p<0.001. n=5-6 animals. 
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4.5.3 Involvement of the JNK pathway 
 
Specific pharmacological inhibitors for JNK (SP600125, 10 μM), ERK1/2 (U0126, 10 μM), 
and p38 (SB203589, 10 μM) pathways were used to explore the role of the MAPK pathways 
in nicotine-induced alteration of TLR expression. SP600125 abrogated the nicotine-induced 
alterations in the mRNA expression of TLR2, -4, -5, and -6, without affecting the TLR1 and -
11 expressions (Fig. 20).  
 
 
 
 
 ´
Figure 20. Effects of specific 
JNK inhibitor SP600125 on 
TLR mRNA expression. Each 
data point is derived from 4 to 7 
animals. P values were 
calculated using two-tailed 
unpaired Student’s t test. *P < 
0.05, **P < 0.01.  
 
Figure 21.  Effects of the specific JNK inhibitor SP600125 on TLR4 (A–C) and TLR6 
(D–F) protein expressions. C, cartilage; Epi, epithelium; SMC, smooth muscle cells. Each 
data point is derived from six experiments. P values were calculated using two-tailed 
unpaired Student’s t test, Nic+DMSO vs Nic+SP600125. ***P < 0.001. 
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U0126 and SB203580 had no significant effect on the TLR expressions (data not shown). 
Analysis of TLR4 protein expressions by immunohistochemistry verified that SP600125 
depressed TLR4 (Fig. 21A-C) and TLR6 (Fig. 21D-F) protein expressions in both smooth 
muscle and epithelium. 
 
4.5.4 Comments 
 
TLR activation is crucial for mounting a forceful immune response against invading 
pathogens. However, excessive activation of TLRs can also cause an overproduction of 
inflammatory cytokines and chemokines as well as an increase in AHR (Starkhammar et al., 
2012). Patients with fatal asthma have been shown to have a more pronounced airway 
expression of TLR3 and TLR4 than healthy control subjects (Ferreira et al., 2012). On the 
other hand, a down-regulation of the TLRs might compromise the host’s immune defense. 
The differential effects of nicotine on the expression of various TLRs might be a reflection of 
the complex nature of smoke-associated airway disease. TLRs are known to be able to form 
heterodimers with each other. For example, upregulated TLR4 and -6 can form heterodimers 
together with the co-receptor CD36. Similar formations have been shown to be of importance 
in atherosclerosis, a disease where cigarette smoking is known to be detrimental (Stewart et 
al., 2010). 
Nicotine per se increased the mRNA expressions of TLR2, -4, and -6, with TLR4 and -6 
showing the largest fold increase. Further analysis of TLR4 and -6 revealed receptor protein 
increases in the epithelium and in the smooth muscle layer. An augmentation of the receptor 
density might explain the amplified LPS sensitivity. The present data are well in line with in 
vivo studies which showed that exposure to cigarette smoke increases the pulmonary 
expression of TLR2 and -4 in mice (Maes et al., 2006). 
The effect of nicotine in cell surface TLR mRNA expressions and TLR4 and 6 protein 
expressions were completely reversed by the inhibition of the MAPK-JNK pathway. The role 
of JNK-related mechanisms in many of the pathological processes in respiratory diseases has 
also been discussed in the recent decade (Bennett, 2006). However, clinical development of 
kinase inhibitors has primarily focused on p38 inhibitors (Adcock et al., 2004). In animal 
studies, it has been found that the JNK inhibitor SP600125 can reduce allergic cellular 
inflammation and ASM proliferation (Eynott et al., 2003) as well as allergen-induced AHR 
(Nath et al., 2005). Our results suggest that JNK may play a special role in cigarette-smoke-
induced pulmonary diseases. 
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4.6 CIGARETTE SMOKE EXPOSURE ON ALK EXPRESSIONS (PAPER V) 
 
4.6.1 Cotinine assay 
 
Twenty seven pairs of tonsils were collected from patients between 15 and 40 years old 
undergoing bilateral tonsillectomy for chronic tonsillitis at the Ear- nose- and throat clinic at 
Malmö University Hospital, Sweden.  
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Figure 22. Local cotinine 
concentrations in tonsil tissue. 
Unpaired Student’s t test was 
used to compare self-reported 
non-smokers with self-reported 
smokers. ** p<0.01.  
Figure 23. IL-8 mRNA expressions in cotinine-verified smokers and non-smokers. 
Unpaired Student’s t test was used to compare IL-8 mRNA levels in non-smokers vs 
smokers (A). * p<0.05. Linear regression was performed relating IL-8 mRNA to local 
cotinine concentration (B). 
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The tonsils were homogenized, centrifuged and the supernatants were analyzed with cotinine 
ELISA. A cut-off level of 80 ng cotinine/g tonsil was used to distinguish smokers from non-
smokers (Fig. 22). This level was chosen to minimize the number of excluded samples. 
The mRNA of IL-8, a cytokine known to be upregulated by cigarette smoke (Agusti et al., 
2012; Lau et al., 2012; Starrett et al., 2011) was significantly higher in the cotinine-verified 
smoker group compared to the cotinine-verified non-smoker group (2.7 folds, p<0.05, Fig. 
23A). A linear positive correlation was found between tonsillar cotinine levels and IL-8 
mRNA levels (r
2
=0.22, p<0.05, Fig. 23B). 
 
4.6.2 ALK expressions 
 
The mRNA expressions of ALK1 and 5 were relatively high in the tonsillar tissue, ALK 2, 3, 
and 4 were lower, while ALK7 was near to undetectable, ALK6 was not detectable at all. 
Significant increases in ALK1 (1.5 fold, p<0.05) and 2 (1.4 fold, p<0.05) mRNA levels were 
found in the cotinine-verified smoker group compared to cotinine-verified non-smoker group 
(Fig. 24A). Both ALK1 and 2 levels displayed linear positive correlations with tonsillar 
cotinine levels (ALK1:  r
2
=0.23, p<0.05, Fig. 24B; ALK2:  r
2
=0.51, p<0.001, Fig. 24C). 
 
4.6.3 Comments 
 
Despite the importance of smoking in a wide range of diseases, patient-reported smoking 
history is notoriously unreliable (Caraballo et al., 2001; Florescu et al., 2009; Hobbs et al., 
2005; Stelmach et al., 2015). This is also reflected in the present study. There can be many 
reasons behind this discrepancy, including memory failure, recall bias, lack of knowledge, 
but also intentional false reporting especially when the social acceptance for smoking in the 
society is decreasing (Caraballo et al., 2001).  A valid estimation of the risks of smoke 
exposure, both active and passive is crucial for the assessment of risks associated with 
smoking. The present study suggests that cotinine measurements in homogenates of tonsils 
can be used to demonstrate local smoke exposure in the tissue. The obtained cotinine levels 
were positively correlated to tonsillar IL-8 mRNA levels. A clear correlation between smoke 
exposure and ALK1 and ALK2 mRNA levels was also seen. 
ALKs are receptors for the transforming growth factor-beta (TGF-) superfamily. They are 
involved in a range of cancer-related cellular processes including proliferation, 
differentiation, adhesion, migration and apoptosis (Graham et al., 2006). Among the seven 
different ALKs found in humans, ALK1 and 5 are the most studied in the context of cancer. 
ALK1 and ALK5 (also termed TGF-βI receptor) exhibit antagonizing effects in endothelial 
cells. While ALK1 promotes growth and proliferation and thereby carcinogenesis, ALK5 
inhibits the same processes (Jonker, 2014). ALK5 knockout mice develop spontaneous 
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squamous cell carcinoma (Honjo et al., 2007). ALK5 expression is also known to be 
decreased in human head and neck squamous cell carcinoma tumor cells (Eisma et al., 1996). 
At the same time, high levels of ALK1 in tumor tissue from patients with head and neck 
squamous cell carcinoma appear to be positively correlated to more advanced TNM stages as 
well as a poor prognosis (Chien et al., 2013). Inhibitors of ALK1 are currently under clinical 
trials for the treatment of solid tumors (Cunha et al., 2011; Jonker, 2014). Blocking ALK1 
signaling using an ALK ligand trap ALK1-Fc in combination with cisplatin was recently 
found to inhibit tumor growth in murine head and neck cancer models more efficiently than 
chemotherapy alone (Hawinkels et al., 2015). The present data supports the role for ALK in the 
poor prognoses that characterize tonsillar cancer among smokers. 
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Figure 24. ALK mRNA levels in tonsils of cotinine-verified smokers and non-
smokers. Unpaired Student’s t test was used to compare  individual ALK mRNA 
levels in non-smokers vs smokers (A). * p<0.05. Linear regression was performed 
relating ALK1 (B) and 2 (C) mRNA levels to tonsillar cotinine concentrations. 
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5 CONCLUSIONS 
 
The present thesis has investigated the effects of nicotine and LPS, alone or in combination, 
on AHR and inflammation.  
 
The main conclusions are the following: 
 
- Long-term nicotine exposure in vitro enhances bradykinin- and des-Arg9-bradykinin-
induced airway contractions in murine tracheal segments. The nicotine effect is 
mediated by activation of neuronal nicotinic receptors which lead to transcriptional 
upregulation of kinin B1 and B2 receptors. This process depends on the activation of 
JNK- and PDE4-related intracellular signalling pathways. 
 
- Short-term nicotine exposure in vitro impaired epithelium-dependent kinin-receptor 
mediated airway relaxations in murine tracheal segments. In addition, nicotine 
suppressed the mRNA and protein expression of mPGES-1 and showed a tendency to 
suppress COX-2. Addition of dexamethasone to the system did not reverse the effects 
of nicotine. 
 
- Long-term nicotine exposure in vitro induced inflammation and upregulated the 
expression of TLR4 and 6 via the MAPK-JNK pathway. In addition, nicotine 
exaggerated LPS-induced AHR. This might explain the increased AHR often seen 
among cigarette smokers when confronted with bacterial infections.  
 
- LPS increased AHR to EFS in vitro and to methacholine in vivo. Long-term nicotine 
exposure markedly dampened this LPS-induced AHR both in vitro and in vivo. The 
effect of nicotine was mimicked by tetrodotoxin, suggesting an important role for 
neuronal mechanisms in cigarette smoke-induced AHR in vivo. 
 
- Measurement of cotinine in tonsil homogenate appears to be a useful and reliable 
method to objectify smoke exposure levels in tonsils. A direct correlation between 
smoke exposure and increased tonsillar expressions of IL-8, ALK1 and 2 were 
demonstrated, suggesting a role for ALK1 in the poor prognosis that characterize 
tonsillar cancer among smokers. 
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6 GENERAL DISCUSSION 
 
6.1 WHY STUDY NICOTINE? 
 
One might wonder why it is necessary to study the effects of nicotine, since everybody 
already knows that smoking is detrimental to health. After the Surgeon General report made 
headlines in the United States and the rest of the world  in 1964, it has been known that 
cigarette smoking causes lung cancer, laryngeal cancer, chronic bronchitis and cardiovascular 
disease. Now, more than 50 years after the publication of this report, the knowledge about the 
spectrum of organ systems negatively affected by smoking has expanded, accompanied by 
drastic changes in attitudes towards smoking (Alberg et al., 2014).  
Indeed, the smoking prevalence is decreasing, especially in Western countries. In Sweden, 
the smoking prevalence has decreased from 27.7% to 12.7% among middle-aged men and 
32.3% to 14.3% among women from the period 1990-1995 to the period 2002-2007. 
However, the use of the Swedish oral moist snuff, has steadily increased from 27.5% to 
33.7% among middle-aged men and rapidly increased from 3.2% to 13.9% among middle-
aged women (Norberg et al., 2011). Also, it should not be forgotten that in non-Western 
countries such as China, the overall smoking prevalence (including both regular smokers and 
former smokers) is still over 70% among men (Paskett et al., 2015). 
Despite falling smoking prevalence, the availability of nicotine in the society is greater now 
than ever. Nicotine replacement products, such as nicotine gum, patch and spray, deliver pure 
nicotine through the oral or nasal mucosa or the skin and reduce the severity of withdrawal 
symptoms and craving of tobacco products. They are generally recommended as first-line 
treatment against tobacco dependence. Their side effects are small and they are often sold 
over-the-counter in most countries (Little et al., 2015). Moreover, e-cigarettes were 
introduced to the European and American markets in 2006, and their sales increased 
dramatically around 2010, quickly surpassing nicotine replacement products and are 
predicted to surpass traditional cigarettes within 10 years. The regulatory status of e-
cigarettes is still unclear in most countries and is a subject of debate (Fagerstrom et al., 2015).   
Given the high prevalence of nicotine exposure in the society today, it is therefore of interest 
to study the long-term physiological and pathophysiological effects of nicotine. 
 
6.2 EXOGENOUS VS ENDOGENOUS NICOTINE RECEPTOR ACTIVATION 
 
In the present thesis, nicotine receptor activation caused by exogenous nicotine that may 
derive from sources such as cigarettes, moist snuff or nicotine replacement products is 
discussed. The concentration of nicotine used in both the in vitro and in vivo studies 
corresponds to that seen among heavy smokers and moist snuff users. For the in vitro studies, 
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nicotine at a concentration of 10 μM was used. This level can roughly be compared to the 
“local exposure” level. In the saliva of smokers during smoking days, the level of nicotine 
measures up  to 8 μM  (Lindell et al., 1993) and 34 μM is found in the induced sputum of 
smokers 5 min after smoking one cigarette (Clunes et al., 2008). 
For the in vivo studies, a level equivalent to “systemic exposure” was used. Subcutaneous 
osmotic pumps containing nicotine tartate salt produces a stable plasma nicotine 
concentration and have long been utilized for the study of chronic nicotine effects. Nicotine at 
24 mg/kg/day supplied via a subcutaneous osmotic pump produces plasma cotinine 
concentration equivalent to that of a human smoker (Dickson et al., 2014). This seemingly 
high nicotine dosage is necessary due to the relative high nicotine metabolism in mice 
compared to other species and is commonly utilized in in vivo nicotine research (Matta et al., 
2007). 
It should be noted that the endogenous neurotransmitter acetylcholine can also bind to and 
activate nicotinic acetylcholine receptors. However, the mode of action is very different 
between normal physiological neurotransmission where the receptors are exposed to a sudden 
high concentration of an agonist and a chronic exposure with a sustained low agonist level. 
The former causes the receptors to rapidly change from resting to activated and then 
desensitization, while the latter can stabilize the receptor in an active or inactive state 
depending on the concentration of agonist (Fenster et al., 1997; Jones et al., 2012). The time 
and concentration of exposure is therefore of crucial importance for the effect of nicotine. 
This is also reflected by results from Paper I and II in the present thesis. 
 
6.3 IN VITRO AND IN VIVO DIFFERENCES? 
 
In Paper I, it was seen that long-term nicotine exposure in mice in vitro caused increased 
AHR measured by the myographs. This was not confirmed by the in vivo study in Paper IV 
where long-term exposure to nicotine alone did not alter AHR measured with flexiVent
TM
.  
At a first glance, the most obvious reason for this inconsistency is probably the difference 
between in vitro and in vivo environments. It is not inconceivable that a piece of tracheal 
tissue free from supporting tissue, neural connections and circulating inflammatory cells 
should react differently to that of a living mouse that has access to liver, kidney, brain and 
blood. However, there are several other differences between the two models that also need to 
be considered. 
The differences between large and small airway in terms of function and physiology have 
been brought to attention during the recent decades (van der Wiel et al., 2013). On the other 
hand, the “united airway hypothesis” suggesting that the respiratory tract, all the way from 
the nose down to the alveoli, should be treated as one single entity, has also gained 
momentum (Grossman, 1997; Passalacqua et al., 2001). In the present thesis, in the in vitro 
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model, the large extra pulmonary airway, trachea is used, while in the in vivo model, the 
contraction of the whole lung is tested, including both large and small intrapulmonary 
airways. However, by applying different oscillation frequencies and fitting into the constant 
phase model, the flexiVent
TM
 system computes three separate variables for airway resistance: 
Newtonian resistance (Rn), tissue damping (G) and tissue elastance (H), where Rn reflects 
AHR in the central airways and G reflects AHR in peripheral airways (Bates et al., 2011). In 
the present study, the effects of nicotine and LPS on Rn and G nearly always follow the same 
pattern and no difference was seen between the central and peripheral airways. 
It is worth noting that in the in vitro model, AHR to kinin receptor agonists was increased, 
but contractile responses to the muscarinic receptor agonist, carbachol remained unaltered. In 
the in vivo model, the muscarinic agonist methacholine was used to elicit airway contractile 
responses as methacholine is the golden standard used to demonstrate AHR in in vivo animal 
models and humans. If the responses to the muscarinic agonists carbachol and methacholine 
are compared in vitro and in vivo, the results are consistent, none of the responses were 
altered by nicotine. 
The role of kinin receptor agonists in AHR is a subject of debate. Early studies have shown 
an extensive role for bradykinin in asthma. Increased bradykinin concentration was found in 
BAL of asthma patients. Bradykinin also specifically acted as a potent bronchoconstrictor in 
asthmatic patients, while it had no effect in normal individuals. (Barnes, 1992). Allergen-
induced AHR to bradykinin was found to be more pronounced than that to methacholine in 
human subjects (Berman et al., 1995). However, the failure of the inhaled selective kinin B2 
receptor inhibitor HOE140 to achieve clinically relevant symptom score improvements in a 
phase II trial for moderate to severe asthma (Akbary et al., 1996) has dampened the interest 
for kinin receptors as a target for the treatment of asthma and/or COPD. In rats, HOE140 
inhibits AHR to bradykinin, but not to acetylcholine (Huang et al., 1999). HOE140 was later 
found to be efficient in the treatment of hereditary angioedema attacks (Cicardi et al., 2010).  
Stimulation of kinin receptors produces different effects dependent on the receptor 
localization. On the ASM, kinin receptors directly activates the inositol 1,4,5-trisphosphate 
(IP3) pathway increasing intracellular Ca
2+
 levels which subsequently activates the cellular 
contractile machinery (Billington et al., 2003). On airway sensory nerves, kinin receptors 
activate the vagal ganglion and thereby initiate the cough reflex (Fox et al., 1996; Grace et 
al., 2012). On the airway epithelium, kinin receptors activate COX and stimulate the release 
of PGE2 from airway epithelial cells which induces airway relaxation through EP receptor 
activation (Barnes, 1992). In in vitro studies, the production of PGE2 was blocked with the 
non-selective COX inhibitor indomethacin, while this is not the case in in vivo studies or 
humans. The complex and sometimes contradictory nature of bradykinin’s effects might be 
the reason behind the failure of the kinin receptor antagonist in clinical trials as an asthma 
drug. 
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6.4 TLR4 EXPRESSION AND RESPONSE TO LPS 
 
TLRs are central players in the innate immune response. They are PRRs and recognize a 
variety of molecular structure of pathogens such as bacteria, virus and fungi.  
In Paper III, both TLR4 mRNA and protein was found to be increased by long-term nicotine 
treatment in vitro. TLR4 protein was predominantly expressed on ASM in fresh segments, 
but after nicotine exposure for 4 days, its expression increased significantly both on ASM and 
epithelium, with a greater percentage increase on the epithelium. This nicotine-induced 
upregulation of TLR4 receptor was believed to be responsible for the synergistic effect 
observed between nicotine and LPS on AHR, making the tracheal segments more sensitive to 
low concentrations of LPS. However, in the in vivo model in Paper IV, despite an increase in 
the protein density of TLR4 on bronchial epithelium following long-term nicotine exposure, 
the AHR to LPS decreased in the nicotine-treated group.   
The clear increase in TLR4 expression but decrease in LPS response seen in vivo is 
somewhat puzzling. One reason could be the fact that only epithelial TLR4 protein 
expression is semi-quantified with immunohistochemistry, while the expression on other 
structures such as ASM and nerves cannot be seen in the immunohistochemistry sections 
used. The ability of tetrodotoxin to inhibit the LPS-induced AHR in vivo, as well as the 
striking similarity between the effect of nicotine and LPS on EFS-responses in vitro, supports 
the role for nerves in the observed decreased LPS responses. Therefore, the TLR4 expression 
in bronchial epithelium might not be important for the development of LPS-induced AHR. 
This is supported by the recent finding that stimulation of TLR4 on different cellular 
compartments contributes to different inflammatory responses. While TLR4 on 
hematopoietic cells is responsible for the neutrophilic inflammation following LPS- and 
house dust mite lysates, TLR4 on airway epithelial cells is mainly responsible for the 
eosinophilic airway inflammation following allergen sensitization and challenge (McAlees et 
al., 2015). 
Another possible explanation for the difference in LPS responses might be due to the 
difference in LPS concentrations. In the in vitro system in paper III, a synergistic effect 
between nicotine and LPS was seen at LPS concentrations of 10
-5
 mg/ml and 10
-4
 mg/ml, but 
not 10
-3
 mg/ml. This was possibly due to the ability of high LPS concentrations to saturate the 
TLR4 receptors and thereby mask the differences in response caused by different TLR4 
receptor density. A much higher LPS concentration (10
-1
 mg/ml) was used in the in vivo 
system in paper IV, compared to that used in vitro.  
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6.5 FUTURE ASPECTS   
 
In the present thesis, the inhibition of MAPK JNK with SP600125 attenuated nicotine-
induced AHR as well as the transcriptional upregulation of TLR in vitro. It might therefore be 
a promising target in the treatment of cigarette-smoke associated airway diseases.  
It is interesting to note that despite the current interest in p38 inhibitors un the treatment of 
COPD (Norman, 2015), no changes in p38 phosphorylation were seen in the in vitro nicotine-
exposure model and the upregulated TLR expression was selectively inhibited by the JNK 
inhibitor SP600125, but not by the p38 inhibitor SB203589. Our group has previously shown 
that cytokine-induced increase in AHR to bradykinin in vitro is also mediated via activation 
of JNK and the downstream transcription factor NF-κB which leads to increased expression 
of kinin receptors (Zhang et al., 2005; Zhang et al., 2004).  
The effect of the specific JNK inhibitor SP600125 has been studied in animal models with 
somewhat different results. It was found to reduce allergic cellular inflammation and ASM 
proliferation, but not AHR in a rat model of chronic allergen exposure (Eynott et al., 2003). 
While in another mice model, SP600125 was found to decrease allergen-induced AHR (Nath 
et al., 2005).  
Over 100 mediators have now been implicated in asthma and COPD inflammation. Blocking 
a single mediator is therefore unlikely to be very effective in this complex disease. So far, 
mediator antagonists have not proved to be very effective compared to drugs that have a 
broad spectrum of anti-inflammatory effects, such as glucocorticoids. MAPKs are therefore 
desirable targets as they are involved in a large number of intracellular activities including 
gene expression, apoptosis, differentiation, proliferation and oncogenesis. However, at the 
same time, with such a broad activity profile, it is not strange that inhibition of MAPK comes 
along with many side effects, a problem that troubles the clinical development of p38 
inhibitors (Adcock et al., 2004). 
One possibility to reduce the side effects could be the use of a combination of drugs in lower 
doses. Paper I revealed cross-talk between the JNK and PDE4 pathways. The PDE4 inhibitor 
Roflumilast is already approved for the treatment of COPD in the clinic. A combination of a 
PDE4 inhibitor with a JNK inhibitor can theoretically lower the concentration of JNK 
inhibitor required and thereby possibly also lower the risk of side effects.  
Paper IV highlighted the involvement of neuronal mechanisms in LPS-induced AHR and its 
modulation by long-term nicotine treatment. While one might not want to return to the 1950s 
and perform surgical denervation and vagotomy on asthma (Levine et al., 1950) and COPD 
(Abbott et al., 1953) patients, recent research find transient receptor potential channels to be 
promising targets. Transient receptor potential channels are mainly found on sensory nerve 
endings. Studies have shown a fivefold increase in the number of nerve profiles that express 
TRPV1 channels in airway biopsies from subjects with chronic cough compared with normal 
controls (Groneberg et al., 2004). Recent study using optogenetics found that activation of 
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TRPV1 positive nerves in the vagal ganglion dramatically exacerbated AHR of inflamed 
airways, which shows that the AHR phenotype can be physiologically dissociated from the 
immune component. The TRPV1 blocker JNJ17203212 (Bhattacharya et al., 2007) and the 
transient receptor potential ankyrin 1 blocker GRC 17536 (Mukhopadhyay et al., 2014; Ryan 
et al., 2014) are currently under development as anti-tussives. 
Paper V found ALK1 to be specifically upregulated in the tonsils of smokers. The effects of 
ALK1 inhibitors for the treatment of solid tumor cancer are currently under intensive study 
(Cunha et al., 2011). Our results suggest that ALK1 inhibitors could be effective for the 
treatment of smokers with tonsillar cancer, a group of patients characterized by poor disease 
prognosis and low response to current therapy.   
In conclusion, the results in the present thesis may contribute to the development of specific 
and personalized treatment strategies for patients exposed to cigarette smoke or nicotine. 
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7 POPULAR SCIENCE SUMMARY IN SWEDISH 
 
Det är välkänt att tobaksrök kan orsaka och förvärra sjukdomar i luftvägar. Tobaksrök ger 
upphov till ökad inflammation och ökad retbarhet i luftrören, så kallad luftvägshyper-
reaktivitet. Rökare svarar sämre på dagens behandlingar mot luftvägssjukdomar och cancer 
och därför är behoven av effektivare och individanpassade behandlingsstrategier stora. 
Tobakrökens negativa inverkan på luftvägarna har inte alltid varit självklart. Astmacigaretter 
innehållande en blandning av olika örter och i många fall också tobak har används under 
minst hälften av 1900-talet för att förebygga och behandla astmaattacker. Detta vittnar om 
den komplexa syn som funnits på tobaksrökens effekter på luftvägarna. De exakta 
mekanismerna bakom tobaksrökens verkan på luftvägshyperreaktivitet och inflammation är 
fortfarande ofullständigt kartlagda. 
Tobaksrök innehåller tusentals olika kemiska ämnen. Avhandlingen har valt att fokusera på 
två av de viktigaste komponenterna, nikotin och endotoxin. Den senare finns också i 
cellväggar hos bakterier och aktiverar det medfödda immunförsvaret. Effekter på lung-
funktionen och på isolerade luftrör av dessa två ämnen enskilt eller tillsammans har studerats 
på möss. Effekterna av tobaksrök studerades också i tonsiller från rökare och matchade icke-
rökare. Målet har varit att identifiera nyckelmolekyler i de signalvägar som är involverade i 
luftvägssjukdomar associerade med tobaksrök. Genom att selektivt hämma dessa signal-
molekyler hoppas vi att nya effektivare behandlingsalternativ skall kunna utvecklas. 
Delarbete 1-IV visar att korttidsexponering för nikotin minskar luftvägarnas förmåga att 
relaxera medan långtidsexponering ökar de glatta muskelcellernas sammandragningsförmåga. 
Långtidsexponering ökar också uttrycket av toll-lika receptorer på luftvägarna. Dessa 
receptorer är en del av vårt medfödda immunförsvar. Ökat toll-lika receptoruttryck ökar den 
glatta muskulaturens  känslighet för långtidsendotoxinstimulering men minskar känsligheten 
för korttidsendotoxinstimulering på nerver. Möss som har exponerats för nikotin under 28 
dagar minskar den endotoxin-inducerade luftvägshyperreaktiviteten. Detta antyder att 
nerverna kan spela en viktig roll i uppkomsten av luftvägshyperreaktivitet.  
Delarbete V visar att tonsiller från rökare uttrycker  höga nivå av interleukin 8 samt activin 
receptor-like kinase (ALK) 1 och 2. Nivåerna korrelerar med mängden lokal rökexponering. 
Interleukin 8 och ALK1 är involverade i såväl uppkomst som spridning av cancer och kan 
bidra till den negativa prognos som rökare med tonsillcancer har.  
Sammanfattningsvis, bidrar både nikotin och endotoxin till utvecklingen av luftvägs-
hyperreaktivitet. Nikotin modifierar dessutom det medfödda immunsystemet och påverkar på 
så sätt känsligheten för endotoxin. Tobaksrök förändrar ALK uttryck i tonsiller och tycks 
påverka cancerprognosen. Dessa resultat kan bidra till utvecklingen av individanpassade 
strategier för behandling av patienter som exponerats för tobaksrök eller ren nikotin, såväl 
aktivt som passivt.  
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